Skip to main content

Table 1 Acute-phase reactants upon admission and during follow-up while receiving canakinumab treatment

From: Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report

  Reference ranges On admission After first administration of canakinumab Last visit
CRP 0-0.1mg/dl 6.5mg/dl 1mg/dl <0.33mg/dl
ESR 0-20mm/hr 100mm/hr 30mm/hr 10mm/hr
SAA 0-8mg/L 123mg/L 13.3mg/L 6.9mg/L
  1. CRP C-reactive protein, ESR erythrocyte sedimentation rate, SAA Serum amyloid A